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SUMMARY
The mammalian genome contains several hundred microRNAs that regulate gene expression through mod-
ulation of target mRNAs. Here, we report a fragile chromosomal region lost in specific hematopoietic malig-
nancies. This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203. This microRNA
is additionally hypermethylated in several hematopoietic tumors, including chronic myelogenous leukemias
and some acute lymphoblastic leukemias. A putative miR-203 target, ABL1, is specifically activated in these
hematopoietic malignancies in some cases as a BCR-ABL1 fusion protein (Philadelphia chromosome). Re-
expression ofmiR-203 reduces ABL1 andBCR-ABL1 fusion protein levels and inhibits tumor cell proliferation
in an ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor, and re-expression of this
microRNA might have therapeutic benefits in specific hematopoietic malignancies.INTRODUCTION
MicroRNAs (miRNAs) are noncoding RNAs 18–25 nt in length
that regulate a variety of biological processes by silencing spe-
cific target genes (Ambros, 2004). miRNAs are well conserved
during evolution, and it has been estimated that about 250–600
miRNAs have been evolutionarily conserved in vertebrates
(Bentwich et al., 2005). Additional nonconserved miRNAs have
also been characterized in primates, and humans are reported
to contain about 800–1000 miRNAs (Bentwich et al., 2005;
Zamore and Haley, 2005). Little is known regarding how miRNA
expression is regulated in mammalian cells. Primary miRNA tran-
scripts are generated by polymerases II and III, and they are usu-
ally capped and polyadenylated (Borchert et al., 2006; Kim and
Nam, 2006). Some miRNAs are clustered and transcribed as
multicistronic primary transcripts, but many others are not clus-496 Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc.tered and are transcribed independently (Ambros, 2004; He and
Hannon, 2004; Landgraf et al., 2007). These miRNAs can down-
regulate various gene products by translational repression when
partially complementary sequences are present in the 30 un-
translated regions (30UTR) of the target mRNAs or by directing
mRNA degradation. Using these posttranscriptional control
mechanisms, mammalian miRNAs appear to target a diversity
of cellular functions, including cell proliferation and differentia-
tion (He and Hannon, 2004).
In the last few years, it has become evident that miRNA
expression is deregulated in human cancer, resulting in specific
oncogenic events reviewed in Calin and Croce (2006) and Es-
quela-Kerscher and Slack (2006). Specific over- or underexpres-
sion has been shown to correlate with particular tumor types (Lu
et al., 2005; Volinia et al., 2006). These changes in expression
might modulate known oncogenes or tumor suppressors. ForSIGNIFICANCE
We describe here a tumor suppressor microRNA, miR-203, that is inactivated in human tumors by both genetic and epige-
netic mechanisms. This microRNA controls the expression levels of ABL1, a classic oncogene extensively characterized in
hematopoietic malignancies. Interestingly, miR-203 also controls the expression levels of the BCR-ABL1 translocation pro-
tein produced by the Philadelphia chromosome, a hallmark of chronic myelogenous leukemia (CML) and some B cell leu-
kemias in children. Re-expression of miR-203 dramatically reduces the proliferation of tumor cells in an ABL1-dependent
manner. These results demonstrate that microRNAs are able to modulate the expression of tumor-specific translocation
proteins. In addition, these data suggest complementary therapeutic opportunities in Philadelphia+ malignancies and
ABL1-overexpressing tumors, including some acute lymphoblastic lymphomas or leukemias.
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miR-203 Controls BCR-ABL Oncogene Expressionexample, let-7, a microRNA that inhibits RAS expression, is
downregulated in lung cancer, leading to increased RAS protein
levels (Johnson et al., 2005). On the other hand, miR-17-5p and
miR-20a modulate the balance between cell death and prolifer-
ation in response to the c-Myc oncogene (O’Donnell et al., 2005).
In some cases, it has been demonstrated that miRNAs are inacti-
vated by specific genetic or epigenetic alterations. Thus, miR-15a
and miR-16-1 are inactivated by deletions or specific transloca-
tions in their chromosomal regions (Calin et al., 2002). In fact,
microRNAs exhibit a high frequency of DNA copy changes that
correlate with altered levels of expression in various human
malignancies (Zhang et al., 2006). Other microRNAs are inacti-
vated by epigenetic mechanisms, and their re-expression by epi-
genetic drugs can lead to downregulation of target oncogenes
(Brueckner et al., 2007; Fazi et al., 2007; Lujambio et al., 2007;
Saito et al., 2006). Altered expression of miRNAs, moreover,
can predict clinical outcome (Calin et al., 2005; Takamizawa
et al., 2004; Yanaihara et al., 2006), suggesting that miRNAs
play an important role in human cancer.
In this study, we have identified a region of mouse chromo-
some 12 (F2 region, conserved in human chromosome 14q32)
that is frequently lost in T cell malignancies. This chromosomal
region is especially rich in microRNAs, since it contains several
clusters of microRNAs and expresses 52 mature microRNAs
(about 12% of the mammalian miRNA genome: miRBase v
10.0). We have narrowed down the fragile site to a region of
about 7 Mb that contains 51 out of these 52 miRNAs. After
miRNA expression profiling, we have detected significant silenc-
ing of one of these miRNAs, miR-203. Since affected tumors
usually lose only one copy of this DNA region, we have investi-
gated whether miR-203 expression is also downregulated by
epigenetic mechanisms. We demonstrate here that miR-203 is
silenced by the loss of one allele and promoter CpG hypermethy-
lation in the remaining DNA copy. We have further identified
ABL1 as one of the targets of miR-203, indicating that both
genetic and epigenetic mechanisms participate in transcriptional
silencing of miR-203, leading to upregulation of the ABL1 and
BCR-ABL1 oncogenes in various murine and human hematopoi-
etic malignancies. Restoration of miR-203 by exogenous trans-
fection or epigenetic drugs results in ABL1 and BCR-ABL1
downregulation (similar to that elicited with RNA interference)
and decreased proliferation of tumor cells. This antiproliferative
effect is partially rescued by overexpression of BCR-ABL1 and
fully rescued by a BCR-ABL1 cDNA without the endogenous
30UTR, suggesting that ABL1 is a crucial target of the tumor
suppressor activity of miR-203.
RESULTS
A Chromosomal Region Enriched in MicroRNAs
Is Frequently Lost in Irradiated T Cell Lymphomas
In a search for genomic alterations throughout the tumor genome,
we performed comparative genome hybridization (CGH) of 12
g-radiation-induced lymphomas versus wild-type tissues from
C57BL/6J mice. We identified consistent DNA losses in the telo-
meric region of chromosome 12 (about 50% of samples; n = 12).
CGH analysis of this fragment (Figure 1A) did not provide resolu-
tion enough to analyze putative candidate tumor suppressor
genes. We therefore further refined this region using specificsingle-strand conformation polymorphism (SSCP) analysis in 44
additional tumor samples using F1 mice generated from crosses
between pure C57BL/6J and RF/J inbred mice. These studies
demonstrated that the DNA fragment most frequently lost in these
tumors corresponds to the chromosome region between markers
D12Mit132 and D12Mit18 (chromosome 12 positions 107.4 to
113.7 Mb) (Figure 1B). This region contains about 80 protein-cod-
ing genes, including Bcl11b, a potential tumor suppressor candi-
date for this region (Wakabayashi et al., 2003). Interestingly, in ad-
dition to these genes, this chromosomal region also contains 52
microRNAs (Figure 1C), accounting for about 12% of the known
microRNAs in the mouse genome (Sanger miRBase repository,
Release 10.0; August 2007) (Griffiths-Jones et al., 2006). These
microRNAs include several clusters located at the callipyge
locus, a chromosomal region known to be regulated by genomic
imprinting (Davis et al., 2005) and other nonclustered microRNAs.
Figure 1. Chromosomal Losses in Mouse Chromosome 12 by CGH
and SSCP Analysis
(A) DNA copy losses detected by CGH in the murine tumors analyzed. The pro-
file shows the area most frequently lost (cytobands F1 and F2) in these murine
T cell malignancies.
(B) Analysis of loss of heterozygosity by SSCP. The different markers used
through the complete chromosome 12 are shown as vertical flags. DNA losses
in cytobands D3 to F2 are shown by the intense colored boxes whereas less
intense boxes indicate blind regions between the closer markers in their
boundaries.
(C) The precise locationofmicroRNAs locatedat the deletedregion (108–115 Mb)
is indicated by vertical lines. The ‘‘callipyge’’ clusters contain 44 additional
microRNAs whose names have been omitted for clarity.Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc. 497
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and Human miR-203
To analyze whether some of these miRNAs were silenced in
T cell malignancies, we performed expression profiling using
miRNA microarrays (Figure 2). High-stringency analysis of these
tumors indicated that only one of these miRNAs, miR-203, was
significantly silenced in murine T cell lymphomas (FDR < 0.001;
D = 1.4; Figure 2B).
Since these murine T cell lymphomas lost expression of miR-
203, despite maintaining a normal allele, we analyzed whether
this miRNA could be silenced by epigenetic mechanisms. miR-
203 presents a clear CpG island in its upstream chromosomal
region flanking the transcriptional start site (TSS) similar to that
present in many tumor suppressor genes (Figure 3). As a control,
we used miR-345, since it also presents a clear CpG island in its
upstream chromosomal region and both are located in the chro-
mosome 12 region deleted in these T cell malignancies. After
bisulfite conversion of genomic DNA from these samples, we
could not detect any methylation at the miR-345 CpG island, in
either normal lymphocytes or tumor samples (Figure S1A avail-
able online). Similarly to miR-345, miR-203 was not methylated
in normal lymphocytes. However, it was significantly methylated
in seven out of eight murine T cell lymphoma tumor samples (Fig-
ure 3). Detailed analysis by bisulfite sequencing indicated that
most of the CpG dinucleotides in this CpG island were methyl-
ated in some tumors but not in normal lymphocytes (Figure 3C).
The chromosome 12 region identified in mouse T cell lympho-
mas is synthenic to a telomeric region in human chromosome 14.
Interestingly, all microRNA clusters and genes located at this re-
gion in the mouse are conserved in the human genome. In fact,
both the miR-203 pre-miR and its putative TSS are highly con-
served between human and mouse genomes (Figure 3B). To
test whether this epigenetic silencing of miR-203 was also pres-
ent in human tumors, we analyzed four human T cell tumor cell
lines (KARPAS-45, PEER, JURKAT and MOLT-4) and three addi-
tional primary peripheral T cell leukemias by methylation-specific
PCR (MS-PCR) analysis. In all these human samples, miR-203
was dramatically hypermethylated as detected by MS-PCR
(Figure S1B) and bisulfite sequencing (Figure 3D), whereas this
sequence was not methylated in human normal T-lymphocytes.
miR-203 Directly Regulates ABL1 Expression
Computational prediction of both human and mouse miRNA
targets (TargetScanS and PicTar [Rajewsky, 2006]) suggests
that miR-203 can modulate more than 300 genes. To further se-
lect a functional miR-203 target, we performed massive mRNA
expression analysis of mouse T cell lymphomas with silenced
miR-203 to identify possible targets upregulated in these tumors.
Twenty-two of the putative miR-203 targets are significantly
overexpressed in these T cell lymphomas (Figure 4A), including
Abl1, the murine homolog of ABL1, a known oncogene in hema-
topoietic malignancies (Ren, 2005). In fact, Abl1 is overex-
pressed in these T cell tumors as detected by protein analysis,
indicating a correlation between Abl1 overexpression (Figure 4B)
and loss of miR-203 in these primary tumors (Figure 4B and
Figure S2). Both the murine and human 30UTR of ABL1 genes
contain miR-203 target sequences with a computed free energy
of 26.8 kcal/mol and 21.0 kcal/mol, respectively (Figure 4C).
This target site is well conserved in other vertebrates (Figure S3),498 Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc.suggesting that miR-203 may control ABL1 levels in a variety of
organisms.
To experimentally validate that miR-203 can target ABL1, we
analyzed ABL1 protein levels in human T cell tumor cell lines after
re-expression of miR-203. KARPAS-45 or PEER cells—both
containing a methylated miR-203 promoter (see Figure 3D)—
were infected with retroviral vectors expressing GFP or coex-
pressing GFP and miR-203. GFP-positive cells were isolated
by cytometry and analyzed by immunoblot. As indicated in Fig-
ure 5, re-expression of miR-203 results in decelerated growth
(doubling time of about 56 hr in both cell lines), compared to
control cells infected with the empty retrovirus (doubling time
of about 24 hr in both control cultures). This antiproliferative
response is accompanied by a dramatic reduction (of about
70%) in ABL1 levels in these tumor lymphocytes in both KAR-
PAS-45 and PEER cell lines (Figure 5 and Figure S4). Interest-
ingly, the antiproliferative effect elicited by miR-203 is similar to
that observed after expressing a pool of four different small-hair-
pin interfering RNAs specific for the humanABL1 gene (Figure 5B
and Figure S4A), suggesting a specific requirement for ABL1 in
these T cell lymphomas.
Figure 2. Microarray Analysis of Chromosome 12 MicroRNA
Expression
(A) Heat map showing the expression of miRNAs located at the deleted region
in mouse chromosome 12 (between position 108 Mb and 115 Mb).
(B) Significance analysis of microarrays in these samples point to miR-203 as
the only miRNA significantly downregulated (FDR < 0.0001) in tumor versus
normal samples.
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miR-203 Controls BCR-ABL Oncogene ExpressionNext, we subcloned the ABL1 30UTR downstream of a lucifer-
ase reporter vector to analyze whether miR-203 directly targets
ABL1 as predicted from the alignment. In 293 cells, miR-203,
but not GFP, is able to reduce luciferase activity in this construct
by 30% (Figure 5C) indicating that this microRNA may directly
target the ABL1 30UTR. This reduction is abolished by a 30UTR
that contains specific point mutations in the seed region of the
miR-203 target sequence (Figure 5C), indicating that miR-203
candirectly influence ABL1 protein levels through specific binding
to its 30UTR.
SpecificMethylation ofmiR-203 in Philadelphia-Positive
Human Leukemias
To further investigate the relevance of miR-203 in the oncogenic
activity of ABL1, we next analyzed the epigenetic silencing of
miR-203 in human tumors carrying a Philadelphia (Ph) chromo-
some. This alteration produces a BCR-ABL1 fusion protein that
drives tumor development in several malignancies including
some B cell acute lymphoblastic leukemias (B cell ALL) in children
andchronicmyelogenous leukemias (CMLs).Asshown in Figure 6
(and Figure S5) the upstream region of the human miR-203 is
heavily hypermethylated in most Ph-positive tumors, including B
cell ALLs and both primary CMLs and cultured CML cell lines.
This methylation correlates with decrease expression in these
Ph-positive tumors (Figure S2B). Interestingly, the miR-203 pro-
moter region is not methylated in other hematopoietic tumors
that do not carry ABL1 alterations. Thus, miR-203 is not signifi-
cantly methylated in acute myelogenous leukemias (AMLs),
chronic myeloproliferative diseases (CMPDs), or additional B
cell ALLs that do not express ABL1 fusion proteins (Figure 6 and
Figure S5). These results suggest a specific pressure to downre-
gulate miR-203 in Ph-positive tumors (CMLs and some B cell ALL)
or tumors that overexpress ABL1 (such as T cell lymphomas).
Modulation of ABL1 and BCR-ABL1 Expression
by miR-203 and Epigenetic Drugs
Reintroduction of miR-203 in the CML cell lines K562 and KCL-22
results in restoration of miR-203 expression and concomitant
reduction of ABL1 protein levels (Figure 7 and Figure S4B). These
cell lines also express the BCR-ABL1 fusion protein resulting
from the Ph chromosome translocation. Importantly, re-expres-
sion of miR-203 also results in reduced BCR-ABL1 levels (Fig-
ure 7A and Figure S4B), likely due to the presence of the ABL1
30UTR in the BCR-ABL1 fusion transcript. This reduction in
Figure 3. DNA Methylation Analysis of miR-203 in
Mouse and Human T Cell Lymphomas and Leukemias
(A) Methylation-specific (MS-PCR) analysis of the miR-203
upstream region in mouse chromosome 12. The percentage
of C+G nucleotides (CG%) and the density of CpG dinucleo-
tides are shown for a region spanning 4 kbp upstream of
miR-203. Specific primers for this CpG island were designed
(convergent arrows) and used to amplify these DNA fragments
in normal and tumor samples. A MS-PCR protocol was fol-
lowed to specifically amplify unmethylated (U) or methylated
(M) DNA. Methylation of miR-203 upstream regions is patent
in most tumor samples (asterisks) but not in normal cells.
T-CL, T cell lymphomas; NL, lymphocytes from normal thy-
muses; IVD, DNA methylated in vitro. H2O indicates amplifica-
tion were H2O was used instead of lymphocyte DNA.
(B) VISTA plot showing the homology between the mouse and
human region upstream miR-203. The two regions with higher
homology correspond to the position of miR-203 and the tran-
scriptional start site (TSS) as identified by computer analysis
(Saini et al., 2007) and paired-end ditag identification
(Ng et al., 2005). Pink areas in VISTA plot indicate the CpG
island. The density of individual CpG dinucleotides is also
shown in red.
(C) Bisulfite sequencing of the miR-203 upstream region in
mouse T cell lymphomas (T-CL) and normal lymphocytes
(NL). No CpG dinucleotides are methylated in control samples,
whereas some tumors such as 16CG63 and NRH5-2 are
heavily methylated.
(D) Similar analysis in human T cell leukemia (T-CL) cell lines or
primary tumors. Nonmethylated CpG dinucleotides are shown
by an empty circle, whereas methyl-CpG is shown by filled
circles. All CpG dinucleotides in a region of about 350 bp
upstream of miR-203 are shown. Three representative tumor
samples are shown for each group, and three independent
clones were sequenced per sample.Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc. 499
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miR-203 Controls BCR-ABL Oncogene ExpressionABL1 and BCR-ABL1 protein levels is accompanied by a dra-
matic decrease in the proliferation rate in these CML cells (Fig-
ure 7B). As in T cells, downregulation of ABL1 and BCR-ABL1
by specific shRNAs results in a similar proliferation arrest. This
arrest is accompanied by apoptotic cell death induced by both
miR-203 and, more dramatically, ABL1 shRNAs (Figure 7C). To
directly analyze whether the translocated ABL1 is a critical target
of miR-203 in this antiproliferative activity in CML cells, we exog-
enously expressed the p210 BCR-ABL1 fusion gene containing
its endogenous 30UTR downstream of the cDNA. This protein
has little effect on K562 or KCL-22 cells (about 10% increase
in cell numbers 3 days after transfection; data not shown) but
Figure 4. Correlation between miR-203 Inactivation and Abl1 Over-
expression in T Cell Lymphomas
(A) Analysis of the expression of putative miR-203 targets by cDNA microarray
analysis. Only 22 miR-203 predicted targets, including Abl1, are significantly
upregulated in these T cell lymphomas as indicated by the significance analy-
sis of microarrays (FDR < 0.001).
(B) Correlation between the downregulation of miR-203 and upregulation of
Abl1 in these tumors. miR-203 expression was detected by northern blot using
U6snRNA as a control. Abl1 expression was monitored at the protein level as
detected by immunoblotting. a-tubulin was used as a loading control. C indi-
cates control (normal thymus) samples, whereas T indicates T cell lymphomas.
These data were quantified and normalized with the corresponding controls.
Histograms represent mean ± SD.
(C) Predicted duplexes formed between miR-203 and the mouse and human 30
untranslated regions (UTR) of ABL1. The seed region is highlighted in a gray
box. The prediction was calculated using the PicTar algorithm (Krek et al.,
2005).500 Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc.results in a significant rescue from miR-203-induced cell arrest
(Figure 7D). As this exogenousBCR-ABL1-30UTR construct con-
tains the miR-203 target site, it probably competes with the en-
dogenous BCR-ABL1 transcript, reducing the titer of miR-203.
We also tested two additional BCR-ABL1 translocation variants
(p210 and p190) devoid of their 30UTR and therefore not contain-
ing miR-203 target sites. As shown in Figure 7D, expression of
these miR-203-resistant BCR-ABL1 cDNAs in K562 and KCL-
22 tumor cells fully overcomes the antiproliferative effect of
miR-203, resulting in a significant increase in cell proliferation.
Finally, since promoter methylation can be reversed using
specific epigenetic drugs, we treated two T cell leukemias, KAR-
PAS-45 and PEER, and two Ph-positive CML cell lines, K562 and
KCL-22, with 50-azacytidine (Aza), 4-phenylbutyrate (PBA), or
a mixture of both drugs. Whereas single treatments with Aza
alone or PBA alone have a minor effect on miR-203 demethyla-
tion in all these cell lines (Figures S6 and S7), the combined treat-
ment results in a partial but efficient demethylation of the miR-
203 upstream region both in T cell leukemias (Figure S6) and
CML cell lines (Figure 8). This combined treatment restores
miR-203 expression, and re-expression of this miRNA strongly
correlates with a significant reduction in both ABL1 and BCR-
ABL1 protein levels (Figure 8 and Figures S6 and S7). These re-
sults suggest that epigenetic drugs, in addition to re-expressing
other methylated cDNAs, can result in oncogene downregulation
mediated by the chemical restoration of miRNA function.
DISCUSSION
It has been recently reported that miRNA loci are frequently
located at fragile sites and suffer frequent genomic alterations
in human cancer (Calin et al., 2004; Zhang et al., 2006). As we
have described here, loss of heterozygosity (LOH) is relatively
frequent in a 7 Mb region surrounding the callipyge locus in
g-radiation-induced T cell lymphomas, a model of neoplasia
that resembles human peripheral T cell lymphomas (Melendez
et al., 2003). This region, located at chromosome 12 in mice
and chromosome 14 in humans, contains some imprinted genes
involved in the regulation of muscle and fat biology (Georges
et al., 2003). Apart from these genes, this region contains a sur-
prisingly high density of miRNAs, including about 12% of the
known mammalian miRNome. Most of these miRNAs are clus-
tered into several transcripts, including six miRNAs at the anti-
Peg11 transcript that participate in the trans regulation of the
Rtl1/Peg11 gene (Davis et al., 2005). About 30 additional miRNAs
are expressed in about four different transcripts downstream of
the callipyge region, although all of these transcripts seem to be
maternally expressed and controlled by genomic imprinting
(Seitz et al., 2003, 2004). In fact, normal lymphocytes display di-
verse methylation of a CpG island flanking miR-134, likely as
a consequence of the genomic imprinting at this locus (M.J.B.
and M.M., unpublished data). The presence of this large number
of miRNAs might confer specific susceptibility to chromosomal
breaks, and large miRNA clusters have been previously sug-
gested to produce fragile sites (Calin et al., 2004).
Among the miRNAs encoded in this area, miR-203 (located
about 2 Mb downstream of the callipyge region) is the only se-
quence significantly downregulated in these T cell lymphomas.
Recent results have indicated that some other microRNAs
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miR-203 Controls BCR-ABL Oncogene Expressionin this area, such as miR-127, are also deregulated in human
tumors by promoter methylation (Saito et al., 2006). We have
demonstrated in this report that specific deletions in this region
are selected in T cell tumor development where miR-203 is spe-
cifically silenced by epigenetics means. Thus, genetic and epi-
genetic mechanisms coordinately inactivate some specific
miRNAs such as miR-203 in these neoplasias.
Expression of miR-203 seems to be restricted to specific cell
types. Thus, miR-203 is significantly expressed in the epidermis
Figure 5. Direct Downregulation of ABL1 by miR-203
(A) ABL1 protein levels in KARPAS-45 cells expressing GFP (GFP) or GFP +
miR-203 (203), indicating a 3-fold reduction of ABL1 levels in the presence
of miR-203. a-tubulin was used as a loading control. ABL1 and a-tubulin sig-
nals were quantified, and their ratio was normalized to that of noninfected cells
(NT). miR-203 transcript levels were quantified by real-time quantitative PCR
and normalized versus the expression levels in NT KARPAS-45 cells (relative
value = 1).
(B) Growth rate of KARPAS-45 and PEER cells expressing miR-203 (filled cir-
cles), a pool of shRNAs against ABL1 (gray circles), or the empty vector (open
circles).
(C) Luciferase activity in DNA constructs carrying the wild-type ABL1 30UTR or
mutated versions (mutated residues are underlined) downstream of the lucifer-
ase reporter. 293 cells were cotransfected with pG-ABL1 (carrying the lucifer-
ase-ABL1-30UTR chimera) and a plasmid expressing GFP or miR-203. The re-
duction in luciferase activity induced by miR-203 expression is reversed after
mutation of three specific residues in the seed region of the miR-203 target
site. Luciferase activity was normalized for transfection levels as indicated in
the experimental procedures. Data shown are representative of separate as-
says at two different luciferase/miRNA ratios as indicated. *Significant differ-
ences at p < 0.001; **no significant differences found. Error bars represent SD.but not in the hair follicles of the skin (Yi et al., 2006). In these cells,
conditional deletion of the miRNA processing enzyme Dicer
results in decreased expression of miR-203 along with other
miRNAs and provokes developmental perturbations in epidermal
organization (Yi et al., 2006). miR-203 is not expressed either in
primary fibroblasts or in many other established cell lines (M.J.B.
and M.M., unpublished data). Moreover, inhibition of miR-203 ex-
pression induces increased cell proliferation (Cheng et al., 2005),
suggesting an antiproliferative function for this miRNA.
Bioinformatics analyses predict that conserved vertebrate
miRNAs target more than 100 to 400 regulatory genes. Among
the putative targets of miR-203, we have validated ABL1 as a rel-
evant target, at least in hematopoietic cells. ABL1 is a nonrecep-
tor tyrosine kinase that is expressed in most tissues and partic-
ipates in the transduction of signals from cell-surface growth
factor and adhesion receptors to regulate cytoskeleton structure
(Ren, 2005). ABL1 is involved in the development of the hemato-
poietic system, and its overexpression is associated with the
development of diverse hematopoietic malignancies (Lin et al.,
2006; Ren, 2005). ABL1 plays an important role in T cell signaling
(Zipfel et al., 2004), mediates resistance to apoptosis in T-lym-
phocytes (Fuchs et al., 1995), and it is overexpressed in T cell
tumors, in some cases as a result of chromosomal translocations
with amplification as reported in the NUP214-ABL1 fusion
(Graux et al., 2004, 2006). As reported in this article, RNAi-medi-
ated downregulation of ABL1 in T cell leukemia cells reduces
proliferation of these tumor cultures (Figure 5), suggesting puta-
tive therapeutic uses of ABL1 inhibitors in these malignancies.
The BCR-ABL1 fusion is a landmark of CML and it is also pres-
ent in a percentage of B cell ALL with poor prognosis. All of these
diseases, but not other Ph-negative leukemias, are accompa-
nied by promoter methylation and decreased expression of
miR-203 (Figures 6 and Supplemental Data), suggesting a prolif-
erative advantage in silencing miR-203 in these tumor cells. It is
also interesting to note that the 14q32 region of human chromo-
some 14 where this miRNA resides is frequently lost in lymphoid
blast crisis of CML patients (Dastugue et al., 1986; Sercan et al.,
2000). It is therefore tempting to speculate that acute transfor-
mation and progression of the disease may be accompanied
by inactivation of tumor suppressor genes in this region, includ-
ing miRNAs such as miR-203.
The recent success of some ABL1-targeted small-molecule
kinase inhibitors in CML and other diseases (Baselga, 2006;
Ren, 2005) has suggested that inhibition of ABL is critical for tumor
treatment in these patients. In fact, CML patients with decreased
levels of BCR-ABL1 transcripts have a significantly lower risk of
disease progression (Druker et al., 2006). The fact that some miR-
NAs suchasmiR-203 can modulateABL1 levels suggests that res-
toration of the expression of these miRNA can be beneficial to ALL
orCML patients carrying the NUP214-ABL1orBCR-ABL1 fusions.
Inaddition, T cell lymphoma/leukemia patientswithhighABL1pro-
tein levels could also benefit from these treatments. Kinase inhib-
itors such as imatinib (Gleevec) do not completely eradicate ABL1-
or BCR-ABL1-expressing cells from the body, and resistance in
some cases emerges as a consequence of point mutations that
render resistant isoforms of ABL1 or by amplification and overex-
pression of the BCR-ABL1 fusion (Shannon, 2002). Since the on-
cogenic transcripts in these translocations contain the target site
for miR-203, our results suggest that restoration of miRNA functionCancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc. 501
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miR-203 Controls BCR-ABL Oncogene Expressionmight provide some beneficial effects for imatinib-resistant pa-
tients. Our data are also in agreement with the finding that epige-
netic drugs such as decitabine display some therapeutic benefits,
even in patients resistant to imatinib (Issa et al., 2005).
EXPERIMENTAL PROCEDURES
Mouse Colony and Induction of Tumors
C57BL/6J and RF/J F1 hybrid mice and pure C57BL/6J animals were main-
tained in our animal facilities following the appropriate ethical recommenda-
tions from our institutions. For tumor induction, 4-week-old mice of both sexes
were exposed to four weekly doses of 1.75 Gy/dose of ionizing gamma radia-
tion (Guerrero et al., 1984) following the protocol approved by our Committee
of Bioethics and Animal Care. These animals were observed in a daily basis,
and sick mice were euthanized humanely in accordance with the Guidelines
for Humane End Points for Animals used in biomedical research. Normal
and tumoral tissues were processed for histological analysis (paraffin embed-
ding and hematoxylin and eosin staining) following standard protocols. DNA,
RNA, and proteins were isolated from these samples as described below.
Comparative Genome Hybridization
For DNA preparation thymic lymphomas and normal tissues were cut, minced
in small pieces, and placed in a microfuge tube containing 0.5 ml lysis buffer
(20 mM Tris-HCL [pH 8.0], 25 mM EDTA, 0.5% SDS, 0.1 M NaCl). Proteinase
K was added at a final concentration of 100 mg/ml and incubated at 55C over-
night. The lysate was extracted twice with an equal volume of phenol:chloro-
form:isoamyl alcohol (25:24:1, v/v) (GIBCO-BRL). DNA was precipitated by ad-
Figure 6. Specific Methylation of miR-203 in
Philadelphia-Positive Human Leukemias
Methylation map of the human miR-203 upstream region in
Philadelphia-positive (Ph+) tumors, including chronic myelog-
enous leukemias (CML) and CML tumor cell lines, and B cell
acute lymphoblastic leukemias (B cell ALL). Additional leuke-
mias that do not contain rearranged ABL1 loci such as Phila-
delphia-negative (Ph) B cell ALL, acute myeloid leukemias
(AML) and other chronic myeloproliferative diseases (CMPD)
are also shown. In these Ph tumors, miR-203 is not signifi-
cantly methylated. Three representative tumor samples are
shown for each group, and three independent clones were
sequenced per tumor sample. Normal blood cells were used
as a control (NBC).
dition of an equal volume of isopropanol and dissolved in TE
buffer (10 mM Tris-HCl [pH 8.0] and 1 mM EDTA).
About 3000 mouse BAC clones with an average spacing of
1 Mb across mouse chromosomes 1 to 19 and the X chromo-
some (Chung et al., 2004) were printed on hydrophobic glass
slide surfaces using an Omni Grid 100 array printer (BioRo-
botics). The average spacing between the linear map
positions of this 3K collection of BAC clones (calculated as
the distance between the midpoint positions of two consec-
utive BACs) is about 0.9 Mb (Chung et al., 2004). For compar-
ative genome hybridization on these BAC microarrays, 1 mg
of tumor or normal DNA was first amplified and labeled
with aminoallyl-dUTP (Sigma, St Louis, USA) using the Bio-
prime random priming kit (GIBCO) and then further labeled
with Cy3 or Cy5 monoreactive NHS esters (Amersham, Pis-
cataway, NJ). DNA samples from six nontreated C57BL/6J
mice were pooled and used as a normal control. Tumor sam-
ples from male animals were hybridized to female pools and
vice versa to have an internal control on DNA gains and los-
ses in chromosomes X and Y. In all, 1 mg of labeled tumor
DNA and an equal amount of control DNA labeled differen-
tially were mixed with 200 mg mouse Cot I DNA (GIBCO), dis-
solved in a formamide-based hybridization buffer containing 50% formam-
ide, 23 SSC, 2% SDS, and 10% dextran sulfate, heat denatured and
annealed at 37C to block repeats, and then hybridized to BAC arrays. Hy-
bridization was carried out in a shaker incubator at 37C for 16–20 hr. Arrays
were washed in 23 SSC, 0.1% SDS at 45C for 60 min and immediately
scanned after rinsing with deionized water. Array images were quantified us-
ing DNA Microarray Scanner G2565BA (Agilent). Array data have been de-
posited in the Gene Expression Omnibus (GEO) database under accession
number GSE10858.
LOH Analysis
LOH analysis was carried out by comparing electrophoresis patterns of tumor
and control DNA. The following chromosome 12 markers were used according
to sequences reported in the Mouse Genome Database: D12Mit240 (position
11.2 Mb), D12Mit136 (30.8 Mb), D12Mit154 (39.8 Mb), D12Mit64 (51.5 Mb),
D12Mit110 (52.9 Mb), D12Mit4 (80.0 Mb), D12Mit239 (89.8 Mb), D12Mit132
(108.2 Mb), D12Mit122 (108.4 Mb), D12Mit53 (108.6 Mb), D12Mit123 (110.0 Mb),
D12Mit18 (114.4 Mb), D12Mit150 (117.1 Mb), and D12Mit144 (120.2 Mb;
all positions refer to NCBI database m37; April 2007; ENSEMBL REL. 48,
DEC. 2007). In addition, a specific polymorphism in the Bcl11b gene was
used at position 109.2 Mb as well as two different SNPs in this region,
rs3700933 (position 116.4 Mb) and rs3683037 (119.4 Mb). The specific
sequences used are available from the authors per request. PCR products
were separated on a 3% agarose, 10% polyacrylamide gel for SSCP analysis.
MicroRNA and cDNA Expression Analysis
MicroRNA expression profiles were performed essentially as described previ-
ously (Liu et al., 2004). Briefly, tumor RNA was isolated using Trizol (Invitrogen),502 Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc.
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described previously (Volinia et al., 2006). These microarrays were hybridized
in 63 SSPE (0.9 M NaCl/60 mM NaH2PO4$H2O/8 mM EDTA [pH 7.4])/30%
formamide at 25C for 18 hr, washed in 0.753 TNT (Tris$HCl/NaCl/Tween
Figure 7. Restoration of miR-203 Expression in Ph-Positive
Tumor Cells Downregulates ABL1 and BCR-ABL1
(A) K562 cells were transfected with GFP or miR-203 vectors. Overexpression
of miR-203 results in decreased ABL1 and BCR-ABL1 protein levels as
detected by immunoblotting. miR-203 transcript levels were quantified by
real-time quantitative PCR and normalized versus the expression levels in non-
transfected K562 cells (relative value = 1). a-tubulin was used as a protein load-
ing control. ABL1, BCR-ABL1, and a-tubulin signals were quantified, and their
ratios were normalized to BCR-ABL1 protein levels in GFP-expressing cells.
(B) Growth rate of K562 and KCL-22 cells expressing miR-203 (filled circles),
a pool of four shRNAs against ABL1 (gray circles), or the empty vector (open
circles).
(C) Apoptotic cell death after transfection with miR-203 or ABL1 shRNAs in
K562 or KCL-22 cell lines. These vectors were cotransfected with a GFP-
expressing plasmid, and apoptosis was monitored with Annexin V staining
5 days after transfection.
(D) K562 or KCL-22 cells were transfected with an empty vector, a vector
expressing miR-203, or a combination of vectors expressing miR-203 and
the BCR-ABL1-30UTR construct or miR-203 and the p210 or p190 forms of
BCR-ABL1 that do not contain the endogenous 30UTR. The overexpression
of BCR-ABL1-30UTR partially rescues the effect of miR-203, whereas the
exogenous expression of miR-203-resistant BCR-ABL1 cDNAs fully rescues
miR-203-mediated cell proliferation arrest. Three days after transfection, the
number of cells was scored and normalized to the original number of cells
transfected (fold increase). Error bars represent SD.20) at 37C for 40 min, and processed by using a method of direct detection
of the biotin-containing transcripts by streptavidin-Alexa Fluor 647 conjugate.
Processed slides were scanned using a microarray scanner, with the laser set
to 635 nm, at fixed PMT setting, and a scan resolution of 10 mm. The SAM (Sta-
tistical Analysis of Microarray) tool included in the TM4 package (http://www.
tm4.org/mev.html) was used to analyze the statistical significance of
microRNA expression data. MicroRNA array data have been deposited in
the GEO database under accession number GSE10891.
cDNA microarray experiments were performed using the CNIO RatonChip
23K (v3). This chip contains both the NIA15K and the 7.4K clone sets from
the National Institute on Aging (http://lgsun.grc.nia.nih.gov/cDNA/cDNA.
html), plus 800 additional clones specifically associated with cancer, angio-
genesis, apoptosis, signal transduction, and stress processes obtained from
either the Fantom1 collection (RIKEN) or the I.M.A.G.E. Consortium (Research
Genetics, Huntsville, AL). About 3000 clones are duplicated to reach a total of
27,648 spots, which included 166 spots containing nonmurine DNA as nega-
tive controls. Total RNA was extracted by combination of Trizol reagent (Invi-
trogen) and purification using the RNeasy Protect kit (QIAGEN, Hilden). The
quality of the RNA was evaluated using the BioAnalyzer system (Agilent).
Twenty-five micrograms of the test or reference amplified RNAs were labeled
with fluorescent Cy5 and Cy3 (Amhersam, Sunnyvale), respectively, using the
SuperScript II RNase H Reverse Transcriptase Kit (Invitrogen, USA).
Figure 8. Restoration of miR-203 Expression and Downregulation
of BCR and BCR-ABL1 by Epigenetic Drugs
(A) The CML cell lines K562 and KCL-22 were treated with the epigenetic drugs
Aza + PBA, resulting in significant demethylation of the miR-203 upstream
region. Three independent clones were sequenced per treated cell line.
(B) Upregulation of miR-203 and concomitant downregulation of ABL1 and
BCR-ABL1 protein levels after 5-aza + PBA treatment in K562 and KCL-22
cells. miR-203 transcript levels were quantified by real-time quantitative
PCR and normalized versus the expression levels in nontreated K562 or
KCL-22 cells (relative value in untreated cells = 1). ABL1, BCR-ABL1, and
a-tubulin signals were quantified, and their ratios were normalized to BCR-
ABL1 protein levels in nontreated cells. Histograms in (B) represent mean ± SD.Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc. 503
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Hybridization buffer (Ambion). In all microarray experiments, each sample was
cohybridized with a pool of amplified RNAs obtained from the Universal Mouse
RNA (Stratagene, La Jolla, CA), used as a reference. After washing, the slides
were scanned in an Agilent G2565BA scanner. Images were then analyzed
with GenePix 5.1 (Axon Instruments, Inc., Union City, CA) and the TM4 soft-
ware. Microarray data have been deposited in the GEO database under acces-
sion number GSE10859, and the entire set of T cell lymphoma arrays can be
accessed under GSE10861.
To validate expression of specific transcripts, total RNA from tumors and cell
lines was isolated using Trizol (Invitrogen). Expression of miR-203 in mouse
tumors was analyzed by northern (NorthernMax, Ambion) or RNA protection
(mirVana, Ambion) assays using a miR-203-specific probe (see Supplemental
Experimental Procedures). 6UsnRNA and miR-16+4 were used as controls in
northern hybridizations and RNA protection assays, respectively. The expres-
sion levels of individual microRNAs were quantified using the mirVana qRT-
PCR miRNA detection kit following the manufacturer’s recommendations
(Ambion). GAPDH served as normalization control. In addition, real-time quan-
titative amplification of miR-203 was performed in triplicate with the TaqMan
MicroRNA assays kit (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions in an Applied Biosystems 7900HT Fast Real-
Time PCR apparatus. Amplification of RNU19 was used for normalization.
The data analysis was done using the SDS (Sequence Detection Systems)
2.2.2 program (Applied Biosystems, Foster City, CA).
DNA Methylation Analysis
The following human cell lines were obtained from the German Collection of Mi-
croorganisms and Cell Cultures (DSMZ): JURKAT, MOLT-4, KARPAS-45, and
PEER (T cell acute lymphoblastic leukemias; T cell ALL); K562, KCL22, and
EM-2 (CMLs). Primary human T cell ALLs (501T1, 3020201, and 220T), CMLs
(51226, 60514, 60515, 07CG1139, 07CG1187, 07CG1212, 07CG1257, and
08B0061), B cell ALLs (06CG664, 06CG630, 60344, 07CG0144, 07CG0178,
07CG0223, 07CG0267, 07CG0331, 07CG0354, 07CG0356, 07CG0407,
07CG0674, 07CG0689, 07CG0750/0806, 07CG0751, 07CG0758, 07CG0912,
07CG0956, 07CG0995, 07CG1001, 07CG1035, 07CG1092, 07CG1214,
08CG0100, and 08CG0115), acute myelogenous leukemias (AMLs: 07B1590,
07CG1192, and 07CG1198), or chronic myeloproliferative diseases (CMPDs:
07CG1165, 07CG1155, and 07CG1197) were obtained from our repository or
were kindly provided by J. Benitez, R. Villuendas, or M.A. Piris (CNIO, Madrid).
Leukemic bone marrow samples were obtained by the Cytogenetics Diagnos-
tics Laboratory at our Center under our approved protocol that complies with
the recommendations included in the Spanish Law for Clinical Diagnostic Lab-
oratories. All used samples had previously informed consent, corresponded to
the remaining exceeding material after diagnosis, and were anonymously
coded. For methylation analysis, specific oligonucleotides were designed us-
ing the MethPrimer (Li and Dahiya, 2002) and Methyl Primer Express Software
v1.0 (Applied Biosystems) to amplify methylated or unmethylated mouse or hu-
man microRNA promoters (Table S1). Analysis of DNA methylation by MS-PCR
or bisulfite sequencing was performed essentially as described previously
(Saito et al., 2006). Briefly, genomic DNA (1 mg) was converted with sodium
bisulfite as previously reported (Frommer et al., 1992). After amplification of
the bisulfite-converted DNA, methylation levels were analyzed by sequencing
of the bisulfite-modified promoter regions.
For demethylation studies, cells were seeded at 43 105 cells per 10 cm dish
24 hr prior to the treatment with 5 mM 50-azacytidine (Aza; Sigma-Aldrich,
St. Louis, MO), 3 mM 4-phenylbutyrate (PBA; Sigma-Aldrich), or a combination
of both drugs. Aza was given at the indicated doses continuously for 72 hr.
After 24 hr of recovery, PBA was given at the indicated doses for 2 days in
the combined protocol.
DNA Transfection and Retroviral Infection
Cultured cells were maintained at logarithmic growth in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium
pyruvate, and 100 units/ml each of penicillin G and streptomycin. To analyze
the effect of DNA demethylation, cells were incubated for 3 days with 1–5 mM
5-aza-20-deoxycytidine (5-aza; Sigma-Aldrich, St. Louis, MO) and/or 1–3 mM
4-phenylbutyric acid (PBA; Sigma-Aldrich). To re-express miR-203 in T cells,
we used a GFP-expressing MSCV-driven retroviral vector (a gift from S. Gon-504 Cancer Cell 13, 496–506, June 2008 ª2008 Elsevier Inc.za´lez and M. Serrano; CNIO, Madrid) or a pBabe-puro-derivative vector con-
taining a 400 bp genomic region around the hsa-miR-203 locus. These vectors
were transfected into 293T cells, and the resulting viruses were incubated on
KARPAS-45 and PEER cells. Three days after infection, GFP-positive cells
were isolated by FACS (Becton Dickinson), and the selected cells were used
for cell proliferation assays or immunoblotting on protein lysates. K562 and
KCL-22 cells were transfected with pBabe-puromycin vectors using a nucleo-
fector apparatus (Amaxa Biosystems, USA) following the manufacturer’s rec-
ommendations. p-Babe-puromycin empty vector was used as a control.
Twenty-four hours after nucleofection, cells were selected with 2 mg/ml of
puromycin during 5 days. After selection cells were maintained in 1 mg/ml of
puromycin and were used for cell proliferation assays. To rescue the antipro-
liferative effect of miR-203, cultured cells were cotransfected with EGFP-
expressing MSCV-driven retroviral vectors that express the BCR-ABL1 fusion
proteins (p210 and p190) (a gift from Veronika Sexl, Medical University of
Vienna; and Isidro Sa´nchez-Garcı´a, CIC-Salamanca) and with a pBabe-puro-
mycin vector expressing miR-203 using nucleofector technology. Cells were
maintained in puromycin selection during 5 days, and then EGFP-positive
cells isolated by FACS were used to determine the cell growth rate. For
RNA interference, four different vectors that express small-hairpin RNAs
against the human ABL1 were used (see Supplemental Experimental Proce-
dures and Table S2). Apoptotic cell death was monitored using an Annexin
V staining kit (PharMingen BD Biosciences) following the manufacturer’s
recommendations.
Protein Analysis and Luciferase Assays
Protein lysates were obtained from tissues or cells using RIPA Cell Lysis buffer
(150 mM NaCl, 50 mM [pH 8] Tris HCl, 0.5% deoxychlorate sodium, 0.1%
sodium dodecyl sulfate, 1% Triton X-100, 1 mM EDTA, and 1 mM EGTA)
and the recommended amounts of Protease Inhibitor Cocktail, Phosphatase
Inhibitor Cocktail 2 (Sigma, St. Louis, MO), and Benzonase (Novagen, Darm-
stadt, Germany). Samples were spun at 20,000 3 g at 4C for 15 min, and
the supernatant was stored at 80C or immediately quantified using a protein
assay (Bio-Rad). Seventy micrograms of protein lysates were loaded onto 8%
polyacrylamide-SDS gels. Proteins were transferred to nitrocellulose mem-
branes (Bio-Rad, Hercules, CA) and probed with ABL1 antibodies (Calbio-
chem, Darmstadt, Germany). In addition, anti-a-tubulin antibody (Sigma, St.
Louis, MO) was used as a loading control. After washing, blots were incubated
with the appropriate secondary antibodies coupled to Alexa Fluor 680 or 800
(Invitrogen). Subsequently, the membrane was scanned using the Odyssey
Infrared Imaging System (Li-Cor Biosciences).
Luciferase constructs were made after amplification of the ABL1 30UTR and
subcloning in a modified pGL3-Control vector (Promega). 293 or HeLa cells
were transfected with 0.3 mg of firefly luciferase reporter vector containing
the ABL1 30UTR and 0.3 mg of the control vector containing Renilla luciferase
pRL-CMV (Promega), using Effectene (QIAGEN). Three micrograms of
pMSCV-203 or the empty vector were used to analyze the effect of microRNA
expression on luciferase signal. Luciferase assays were performed 48 hr after
transfection using the Dual Luciferase Reporter Assay System (Promega). Fire-
fly luciferase was normalized to Renilla luciferase activity.
ACCESSION NUMBERS
Array data have been deposited in the Gene Expression Omnibus (GEO) data-
base (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE10858.
MicroRNA array data have been deposited in the GEO database under acces-
sion number GSE10891. Microarray data have been deposited in the GEO
database under accession number GSE10859, and the entire set of T cell
lymphoma arrays can be accessed under GSE10861.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
seven supplemental figures, and two supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/6/
496/DC1/.
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